To include your compound in the COVID-19 Resource Center, submit it here.

ALT-711: Phase II

ALT said that in a double-blind, placebo-controlled U.S. Phase IIa study, patients receiving 210 mg

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE